FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1839-1840 June 19, 1997 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Post Coronary Artery Bypass Graft Trial Investigators PubMed Citation

To the Editor: The Post Coronary Artery Bypass Graft Trial Investigators (Jan. 16 issue)¹ report promising results of aggressive lowering of low-density lipoprotein (LDL) cholesterol levels with lovastatin, which reduced the progression of atherosclerosis in saphenous-vein grafts in patients who had undergone coronary-artery bypass grafting. The study also showed a significantly lower rate of revascularization in the aggressive-treatment group over a period of four years (6.5 percent, vs. 9.2 percent in the moderate-treatment group; P<0.03). The trial investigators and the authors of the accompanying editorial ² point out the study's lack of power to detect a benefit in terms of other . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.